EMS, Brazil's largest pharmaceutical company, has acquired EMS Realtech for an undisclosed amount. This corporate acquisition marks a strategic expansion for the market leader.
EMS, a company founded over 60 years ago with 100% national capital, has held the top position in the Brazilian pharmaceutical market for 19 consecutive years. A part of Grupo NC, a major Brazilian conglomerate, EMS leads the generics segment and maintains a strong presence across pharmacies nationwide. Its operations span Medical Prescription, Generics, Brands, OTC, and Hospitalar segments, producing medicines for nearly all medical specialties from its factories in Hortolândia, Manaus, Brasília, and Jaguariúna. The company is also noted for its advanced Research & Development centers in Brazil and Italy, and its global innovative footprint through entities like Brace Pharma in the United States and Vero Biotech, which recently secured FDA approval for a revolutionary product.
This acquisition is set to strengthen EMS's operational capabilities and strategic infrastructure. While specific details of EMS Realtech's activities were not disclosed, the move aligns with EMS's consistent investments in advanced manufacturing infrastructure and cutting-edge technology to support its extensive product portfolio and global expansion. The integration of EMS Realtech is expected to enhance efficiency and innovation across EMS's diverse pharmaceutical operations, ensuring continued leadership in a dynamic healthcare landscape.
The combination of EMS's deep market presence and R&D prowess with EMS Realtech's contributions is anticipated to foster new avenues for operational excellence and technological integration. This strategic step reinforces EMS's commitment to delivering innovative, effective, and safe products to a growing global market. The combined entity is poised to further consolidate its leadership, ensuring it continues to care for individuals seeking improved health and well-being.